EGFR and non-small cell lung carcinoma: Improvement in clinical outcome, in terms of objective response rate (ORR), progression-free survival (PFS) and overall survival (OS), compared with upfront platinum doublet chemotherapy, made TKIs standard of care for advanced stage EGFR mutant NSCLC (4–8).